The clinical utility of the percent of positive prostate biopsies in predicting prostate-speci®c antigen (PSA) outcome following radical prostatectomy (RP), or external beam radiation therapy (RT), for men with PSA detected, or clinically palpable prostate cancer was investigated.
Introduction
The prostate-speci®c antigen (PSA) level, biopsy Gleason score, and the 1992 American Joint Commission on Cancer (AJCC) clinical T-stage have been established as the ®rst step towards de®ning the probability of organ con®ned prostate cancer in an individual patient prior to the delivery of de®nitive treatment. 1 Yet, while ®nding organ con®ned prostate cancer at the time of pathologic sectioning of the radical prostatectomy (RP) specimen is a favorable prognostic factor, it does not guarantee PSA control. PSA failure occurs despite pathologic evidence of organ con®ned disease in some men. 2 ± 3 Previously published studies 4 ± 6 con®rm that the serum PSA level, 1992 AJCC clinical T-stage, and biopsy Gleason score are independent predictors of PSA failure free survival after either RP or external beam radiation therapy (RT). Risk groups based on the PSA, biopsy Gleason score, and the 1992 AJCC clinical T-stage de®n-ing the risk of PSA failure after RP or RT have been published previously. 7 This study had two goals. The ®rst goal was to establish whether the percent of positive prostate biopsies provided further clarity in predicting PSA outcome following RP after accounting for the previously published prognostic risk group 7 in men with PSA detected or clinically palpable prostate cancer. The second goal was to test the results using a validation analysis that utilized an independent surgical and radiation data set. Particular attention was given to the patients classi®ed in the intermediate risk group 7 where improvements in the prediction of PSA outcome are most needed.
Methods
Patient population. Nine hundred and sixty men treated with a radical prostatectomy and bilateral pelvic lymph node dissection at the Hospital of the University of Pennsylvania (PENN) between 1989 and 1998 who had PSA detected or clinically palpable prostate cancer comprised the study population. Patients receiving neo-adjuvant androgen suppression therapy or adjuvant radiation and/or androgen suppression therapy were excluded. 823 men treated with a radical prostatectomy and bilateral pelvic lymph node dissection at the Brigham and Women's Hospital (B&W) and 473 men treated using 3-dimensional conformal external beam radiation therapy at the Joint Center for Radiation Therapy between 1989 and 1998 who had PSA detected or clinically palpable prostate cancer comprised the validation cohorts.
Preoperative staging. In all cases staging evaluation included a history and physical examination including a digital rectal exam (DRE), serum PSA, computed tomography (CT) of the pelvis or an endorectal and pelvic coil magnetic resonance imaging (MRI) scan of the prostate and pelvis, bone scan, and a transrectal ultrasound guided (TRUS) needle biopsy of the prostate with Gleason score histologic grading. 8 The prostate biopsy was performed using an 18 gauge *Tru-Cut needle via a transrectal approach. Sextant biopsies were obtained in the majority of RP (56%) managed patients at PENN and at the B&W (75%). The remaining 44% of patients managed with RP at PENN had`6 (18%) or b6 (26%) biopsies. The clinical stage was obtained from the DRE ®ndings using the current 1992 AJCC staging system. 9 Radiologic and biopsy information were not used to determine clinical stage. The PSA was obtained on an ambulatory basis prior to radiologic studies and biopsy. All PSA measurements 10 were made using the Hybritech, Tosoh, or Abbot assays.
Treatment. A single referee genitourinary pathologist reviewed the diagnostic biopsy specimens for all patients undergoing surgery at the Hospital of the University of Pennsylvania (JET) or the Brigham and Women's Hospital and the Joint Center for Radiation Therapy (AAR). Surgical treatment consisted of a radical retropublic prostatectomy and bilateral pelvic lymph node sampling. If the intraoperative frozen sections of any sampled lymph node were positive for carcinoma then the radical prostatectomy was aborted. Three dimensional conformal external beam radiation therapy using a 4-®eld technique was performed to a median dose of 70.2 (69 ± 72) Gy after normalization for patients managed at the Joint Center for Radiation Therapy.
Follow up. The median follow up of the 960 and 823 surgically managed patients at PENN and the B & W was 46 months (8 ± 100 months) and 52 months (8 ± 118 months) respectively. The median follow up of the 473 radiation managed patients was 46 months (12 ± 100). The patients were seen 1 month following the end of treatment then at 3 months intervals for 2 y, very 6 months for 5 y, and annually thereafter. At each follow-up a serum PSA was obtained prior to performing the DRE. All pretreatment PSA values were obtained within 1 month of the date of surgery or start of radiation therapy. There were no patients lost to follow up.
Statistical analyses. Patients with 1992 AJCC clinical stage T 1a or T 1b disease were excluded because the diagnosis of prostate cancer in these cases was made on the basis of a transurethral resection sample of the prostate and not through the use of multiple needle biopsy specimens.
PSA failure was de®ned when two consecutive detectable PSA values were obtained after an undetectable value. Time zero was de®ned as the date of surgery or end of radiation therapy for all patients. If a PSA never became undetectable postoperatively, then PSA failure was de®ned to be at time equal to zero. Patients found to have positive pelvic lymph nodes at the time of frozen section or at ®nal pathologic section were stated on androgen suppression therapy and therefore, were considered treatment failures at time zero. PSA failure was de®ned according to the ASTRO consensus de®nition for RT managed patients. 11 Three risk groups* previously de®ned 7 from a review of the literature 12 ± 23 that are based on the pre-treatment PSA level, biopsy Gleason score, and 1992 AJCC T-stage were used to illustrate the impact that the percent positive biopsy information had on the PSA failure free (bNED) survival rates following RP. Speci®cally, PSA failure free survival strati®ed by`34%, 34% ± 50% and b50% percent positive biopsies was estimated using the actuarial method of Kaplan and Meier 24 and graphically displayed. The breakpoints for the percent positive biopsy variable were selected in order to evaluate the clinical utility of this parameter and were de®ned prior to performing the statistical analysis.
A validation analysis of the ability of the percent positive biopsies to stratify PSA outcome following RP was performed using an independent surgical database consisting of 823 men and a radiation data base consisting of 473 men with clinically localized prostate cancer managed at a separate institution during the same time period as the study cohort.
Results
Risk group based analysis. Figure 1 illustrates the value of the previously described risk group system 7 based on the preoperative PSA level, biopsy Gleason score, and 1992 AJCC clinical T-stage. All pairwise comparisons are signi®cant with a P-value`0.0001. Figures 2 ± 4 Validation analysis. Figure 5 shows that the percent positive biopsy categorization of`34%, 34% ± 50%, and b50% successfully strati®ed the surgical validation cohort in the intermediate risk group in a statistically (all pairwise P-values 0.0001) and clinically signi®cant manner. Speci®cally, 251 or 78% of the 322 intermediate risk patients could be classi®ed into either an 8% or 93% Figure 1 PSA failure free survival strati®ed by the risk group de®ned using the PSA value, biopsy Gleason score, and 1992 AJCC clinical T-stage for study patients managed using a radical retropubic prostatectomy. Pairwise P-values: Low vs Intermediate; P`0.0001; Intermediate vs High, P`0.0001; Low vs High, P`0.0001. Figure 2 PSA failure free survival strati®ed by the percent positive biopsies for low risk study patients managed using a radical retropubic prostatectomy. Pairwise P-values:`34% vs b34% ± 50%; P 0.05; b34% ± 50% vs b50% P 0.09;`34% vs b50%, P`0.0001.
Percent positive biopsies and PSA outcome after RP or RT AV D'Amico et al 5-year PSA control cohort using the preoperative prostate biopsy data. Similarly, the majority of the RT managed patients (158/207 (76%)) in the intermediate risk group could also be classi®ed into either a 30% or 85% 5 year PSA control high or low risk cohort respectively using the preoperative prostate biopsy data as shown in Figure 6 . Therefore of the 473 study patients, all but 49 (10%) were classi®ed into high or low risk groups regarding PSA outcome after RT using the percent positive prostate biopsies, PSA level, biopsy Gleason score, and the 1992 AJCC clinical T-stage.
Discussion
In this study, the prognostic signi®cance of the percent positive prostate biopsies was evaluated in a group of men undergoing RP or 3-D conformal external beam RT and was found to be clinically relevant. In particular, Figure 3 PSA failure free survival strati®ed by the percent positive biopsies for intermediate risk study patients managed using a radical retropubic prostatectomy. Pairwise P-values:`34% vs b34% ± 50%, P 0.001; b34% ± 50% vs b50%, P 0.03;`34% vs b50%, P`0.0001. Figure 4 PSA failure free survival strati®ed by the percent positive biopsies for high risk study patients managed using a radical retropubic prostatectomy. Pairwise P-values:`34% vs b34% ± 50%, P 0.001; b34% ± 50% vs b50%, P 0.03;`34% vs b50%, P`0.0001. Several issues remain that need to be addressed. First, in practice, some patients will have prostate biopsies obtained that are not random or not sextant. The results of this study depended upon a random sampling of the prostate gland. The results of this study not apply cases in which a random sample is not obtained (eg directed biopsy of a palpable nodule) or in which the number samples obtained is small (ie`4 samples). Because all patients in this study had random samples and at least 4 Figure 5 PSA failure free survival strati®ed by the percent positive biopsies for intermediate risk validation patients managed using a radical retropubic prostatectomy. Pairwise P-values:`34% vs b34% ± 50%, P`0.0001; b34% ± 50% vs b50%, P 0.0001;`34% vs b50%, P`0.0001. Figure 6 PSA failure free survival strati®ed by the percent positive biopsies for the 207 intermediate risk patients managed using external beam radiation therapy. Pairwise P-values:`34% vs b34% ± 50%, P 0.02; b34% ± 50% vs b50%, P 0.06;`34% vs b50%, P 0.002.
Percent positive biopsies and PSA outcome after RP or RT AV D'Amico et al cores obtained means that these data may not be applicable in cases where less than 4 cores were obtained or a non-random sample was performed.
Second, the results of this study are based on PSA control and not cause speci®c survival. While data is accumulating suggesting that PSA failure may eventually serve as a surrogate for prostate cancer speci®c survival, this association awaits validation and assumes that a patient with PSA failure is not likely to die of other causes. Two reports supporting PSA as a surrogate for prostate cancer speci®c survival following RP have been reported.
One study 25 in which patients underwent a radical perineal prostatectomy showed that the median time to death from prostate cancer after PSA failure was inversely related to the prostatectomy Gleason score. The second study by Pound and colleagues 26 reported that time to PSA failure was a signi®cant predictor of time to distant failure. The time to distant failure was the only signi®cant predictor for death from prostate cancer. While these surgical series support the concept of PSA as a surrogate for cause speci®c survival, validation of this ®nding for patients undergoing external beam radiation therapy is needed. The validation of this ®nding in radiation managed patients is particularly relevant given that in general RT managed patients are older and have a higher rate of comorbid illness compared to a surgically managed cohort. Both of these factors could limit the likelihood that a patient treated with external beam RT will live long enough following PSA failure to experience death from prostate cancer.
In conclusion, the percent of positive prostate biopsies is information that is routinely available on newly diagnosed prostate cancer patients. This information has now been shown in both RP and RT managed patients to provide a clinically signi®cant improvement in predicting PSA outcome in intermediate risk patients where improved outcome prediction is most needed. Therefore, the precent positive prostate biopsies should be considered in conjunction with the PSA level, biopsy Gleason score, and 1992 AJCC clinical T-stage when counseling patients with newly diagnosed and clinically localized prostate cancer about PSA outcome following RP or RT.
